$PASG

Passage BIO, Inc.

Passage Bio is a clinical-stage genetic medicines company focused on developing gene therapies for patients with neurodegenerative diseases. Its lead clinical candidate, PBFT02, is an AAV1 gene replacement therapy delivered by intra cisterna magna administration. It is being studied in the upliFT-D trial for frontotemporal dementia caused by progranulin deficiency, and the trial also includes patients with FTD linked to C9orf72 mutations. Passage Bio is evaluating PBFT02 for other conditions, including amyotrophic lateral sclerosis and Alzheimer’s disease. Passage Bio also has a preclinical Huntington’s disease program through a research collaboration and license agreement with Gemma Biotherapeutics. The program aims to suppress MSH3 expression in the brain using AAV-mediated delivery of a miRNA gene. Passage Bio has sublicensed three pediatric programs to Gemma and has options to license programs for four additional new CNS disease indications. Passage Bio is headquartered in Philadelphia, Pennsylvania.

0
0
1

No SEC Form 4 filings for $PASG in the last 30 days.

See all $PASG insider activity →
Med

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.

Passage Bio 3Q 2026: EPS ($1.47) — 10-Q Summary

Passage Bio reported no revenue and a narrowed net loss of $4.72M for 3Q 2026, with EPS at ($1.47). The company wound down gene therapy programs, completed workforce restructuring, and expects to close a merger in 4Q 2026. Cash reserves were $20.2M, potentially insufficient for 12 months of operations.

Passage BIO, Inc. (PASG): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Equity Incentive Plan On November 5, 2026, Passage Bio, Inc. (“ Passage Bio ”) held a Special Meeting of Stockholders

PASG sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning PASG (Passage BIO, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent PASG coverage spans corporate actions, financial news and earnings.

What's driving PASG

  • Noncompliance risk is a near-term overhang, but the company frames merger closing as the path back to compliance.

    tradingview.com · Nov 18, 2026

  • The disclosed financial decline and cash runway raise downside risk, while the approved merger may provide a catalyst.

    tradingview.com · Nov 10, 2026

  • The merger and new equity plan could dilute existing shareholders and introduce share count changes, creating short‑term pressure on the stock.

    SEC EDGAR 8-K · Nov 6, 2026

  • The amendment restructures the two‑step merger and adds pre‑funded warrants, potentially diluting existing shareholders but securing financing.

    SEC EDGAR 8-K · Sep 3, 2026

  • The filing combines worsening quarterly losses with multiple execution risks (gene-therapy wind-down, restructuring progress, and merger closing/liquidity dependence).

    tradingview.com · Aug 10, 2026

AlphAI scores every news story that mentions PASG with an AI model for sentiment and relevance, and aggregates insider trades from Passage BIO, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PASG

Score

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.

Passage Bio 3Q 2026: EPS ($1.47) — 10-Q Summary

Passage Bio reported no revenue and a narrowed net loss of $4.72M for 3Q 2026, with EPS at ($1.47). The company wound down gene therapy programs, completed workforce restructuring, and expects to close a merger in 4Q 2026. Cash reserves were $20.2M, potentially insufficient for 12 months of operations.

$PASGLowStock split

Passage BIO, Inc. (PASG): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Equity Incentive Plan On November 5, 2026, Passage Bio, Inc. (“ Passage Bio ”) held a Special Meeting of Stockholders

$PASGMedM&A· acquirer · definitive

Passage BIO, Inc. (PASG): Entry into a Material Definitive Agreement

Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Amended and Restated Merger Agreement As previously disclosed, on June 24, 2026, Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”), Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the

$PASGMedM&A· acquirer · definitive

Passage BIO, Inc. (PASG): Entry into a Material Definitive Agreement

Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2618476d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: PASSAGE BIO, INC.; PEREGRINE MERGER SUB, INC.; and REMIX THERAPEUTICS, INC. Dated as of June 24, 2026 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATIVE PROVISIONS 3 1.1

Oppenheimer initiates Passage Bio stock with outperform rating

Oppenheimer has initiated coverage of Passage Bio Inc. (NASDAQ:PASG) with an outperform rating and a price target of $30.00, suggesting a significant upside of 385% from its current price. The firm believes the stock's 46% year-to-date decline is an overreaction to competitor program failures and regulatory concerns, presenting a buying opportunity. Oppenheimer highlighted key differentiators for Passage Bio's lead asset PBFT02 in frontotemporal dementia, projecting $1 billion in peak risk-adjusted sales by 2040.

Related tickers